Literature DB >> 17566852

Low incidence of nonsentinel node-positivity after complete lymph node dissection in melanoma patients with positive sentinel nodes.

Arata Tsutsumida, Hiroshi Furukawa, Yuhei Yamamoto, Katsumi Horiuchi, Tetsunori Yoshida, Satoru Fujii.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17566852     DOI： 10.1007/s10147-006-0639-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  5 in total

1.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

2.  A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma.

Authors:  H Starz; B R Balda; K U Krämer; H Büchels; H Wang
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

3.  Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.

Authors:  Sandra L Wong; Donald L Morton; John F Thompson; Jeffrey E Gershenwald; Stanley P L Leong; Douglas S Reintgen; Haim Gutman; Michael S Sabel; Grant W Carlson; Kelly M McMasters; Douglas S Tyler; James S Goydos; Alexander M M Eggermont; Omgo E Nieweg; A Benedict Cosimi; Adam I Riker; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2006-04-12       Impact factor: 5.344

4.  Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma.

Authors:  Richard A Scolyer; Ling-Xi L Li; Stanley W McCarthy; Helen M Shaw; Jonathan R Stretch; Raghwa Sharma; John F Thompson
Journal:  Am J Clin Pathol       Date:  2004-10       Impact factor: 2.493

5.  Prediction of nonsentinel lymph node status in melanoma.

Authors:  Mark E Reeves; Ruby Delgado; Klaus J Busam; Mary S Brady; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.